Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 10Gynecologic 5Thoracic 3Head & Neck 3Other solid neoplasm 1NET 1Lymphoid 1Genitourinary 1Endocrine 1Dermatologic 1Breast 1

Conditions

Mesothelioma 3Endometrial Neoplasms 2Vulvar Neoplasms 1Uterine Cervical Neoplasms 1Thyroid Neoplasms 1Solid Tumors Harboring NTRK Fusion 1Solid Tumors 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Salivary Gland Neoplasms 1Parotid Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neuroendocrine Tumors 1Neoplasms 1Microsatellite Unstable Colorectal Cancer 1Microsatellite Instability 1Mesothelioma, Malignant 1Melanoma 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Low-grade Glioma 1Locally Advanced Solid Tumors 1KRAS p.G12C Mutant Advanced Solid Tumors 1Head and Neck Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Transitional Cell 1Carcinoma, Small Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × Parkinson Disease 4, Autosomal Dominant Lewy Body × Other solid neoplasm × Clear all
NCT02628067 2025-09-22

KEYNOTE 158

Merck Sharp & Dohme LLC

Phase 2 Active not recruiting
1,609 enrolled 4 FDA
EndocrineGastrointestinalGynecologicHead & NeckNETOther solid neoplasmThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Anus Neoplasms, Bile Duct Neoplasms, Biliary Tract Neoplasms, Carcinoid Tumor, Uterine Cervical Neoplasms, Mesothelioma, Parotid Neoplasms, Salivary Gland Neoplasms, Thyroid Neoplasms, Vulvar Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Neuroendocrine Tumors, Microsatellite Instability, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡